World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
49641
World Ranking
9099
National Ranking
885

Overview

Quentin M. Anstee is affiliated with Newcastle University in the United Kingdom. Their work focuses primarily in the field of Medicine, with specific attention to Epidemiology, Hepatology, Endocrinology, Diabetes and Metabolism, Surgery, and Physiology.

Their research spans several main topics including Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Liver Diseases and Immunity, Diet, Metabolism, and Disease, Hepatitis C virus research, Hepatocellular Carcinoma Treatment and Prognosis, and Endoplasmic Reticulum Stress and Disease.

Recent papers contributed to by Quentin M. Anstee include:

  • A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement, 2020, Journal of Hepatology
  • MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease, 2020, Gastroenterology
  • A multisociety Delphi consensus statement on new fatty liver disease nomenclature, 2023, Hepatology
  • A multisociety Delphi consensus statement on new fatty liver disease nomenclature, 2023, Journal of Hepatology
  • A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis, 2024, New England Journal of Medicine

Frequent co-authors with whom Quentin M. Anstee has collaborated include:

  • Vlad Ratziu
  • Elisabetta Bugianesi
  • Jörn M. Schattenberg
  • Stephen A. Harrison
  • Arun J. Sanyal

Their work has been frequently published in journals such as:

  • Journal of Hepatology
  • Hepatology
  • Gastroenterology
  • JHEP Reports
  • Digestive and Liver Disease

Best Publications

  • Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

    Zobair Younossi;Quentin M. Anstee;Milena Marietti;Timothy Hardy;Timothy Hardy

  • A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

    Mohammed Eslam;Philip N. Newsome;Shiv K. Sarin;Quentin M. Anstee

  • Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030

    Chris Estes;Quentin M. Anstee;Maria Teresa Arias-Loste;Heike Bantel

  • Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

    Quentin M. Anstee;Giovanni Targher;Christopher P. Day

  • From NASH to HCC: current concepts and future challenges.

    Quentin M Anstee;Quentin M Anstee;Helen L Reeves;Helen L Reeves;Elena Kotsiliti;Olivier Govaere

  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Dominik Pfister;Dominik Pfister;Nicolás Gonzalo Núñez;Roser Pinyol;Olivier Govaere

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa

  • Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

    Stuart McPherson;Stuart McPherson;Tim Hardy;Elsbeth Henderson;Alastair D. Burt;Alastair D. Burt

  • Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

    Peter J. Eddowes;Magali Sasso;Michael Allison;Emmanouil Tsochatzis

  • Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

    Leon A Adams;Quentin M Anstee;Herbert Tilg;Giovanni Targher

  • Mouse models in non-alcoholic fatty liver disease and steatohepatitis research

    Quentin M. Anstee;Robert D. Goldin

  • Cellular senescence drives age-dependent hepatic steatosis.

    Mikolaj Ogrodnik;Satomi Miwa;Tamar Tchkonia;Dina Tiniakos;Dina Tiniakos

  • Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

    Rod S. Taylor;Rebecca J. Taylor;Sue Bayliss;Hannes Hagström

  • Advancing the global public health agenda for NAFLD: a consensus statement.

    Jeffrey V Lazarus;Henry E Mark;Quentin M Anstee;Juan Pablo Arab

  • Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

    Stuart McPherson;Stuart McPherson;Tim Hardy;Tim Hardy;Jean-Francois Dufour;Salvatore Petta

  • TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

    Yang-Lin Liu;Helen L Reeves;Alastair D Burt;Dina Tiniakos

  • FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.

    Philip N Newsome;Philip N Newsome;Magali Sasso;Jonathan J Deeks;Jonathan J Deeks;Angelo Paredes

  • Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum

    Timothy Hardy;Fiona Oakley;Quentin M. Anstee;Christopher P. Day

  • Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma

    Y-L Liu;G L Patman;J B S Leathart;Anne Christine Piguet

  • Inflammation-induced IgA + cells dismantle anti-liver cancer immunity

    Shabnam Shalapour;Xue Jia Lin;Xue Jia Lin;Ingmar N. Bastian;John Brain

Frequent Co-Authors

Christopher P. Day
Christopher P. Day Newcastle University
Elisabetta Bugianesi
Elisabetta Bugianesi University of Turin
Arun J. Sanyal
Arun J. Sanyal Virginia Commonwealth University
Mark Thursz
Mark Thursz Imperial College London
Alastair D. Burt
Alastair D. Burt Newcastle University
Manuel Romero-Gómez
Manuel Romero-Gómez University of Seville
Robert D. Goldin
Robert D. Goldin Imperial College London
Zobair M. Younossi
Zobair M. Younossi Inova Health System
Ann K. Daly
Ann K. Daly Newcastle University
Luca Valenti
Luca Valenti University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn't just mean becoming a doctor. Numerous online degree programs offer flexible pathways to thriving healthcare careers. For example, medical billing and coding schools that accept fafsa make it possible to enter the healthcare field without large upfront costs, offering crucial administrative support roles.

Hands-on patient care is another popular path. Many students are looking for nursing programs without teas, which remove standardized testing barriers and streamline the admission process.

For those interested in leadership, healthcare administration degrees can be completed online and quickly prepare graduates for roles in management and policy-making.

Nurses seeking advancement can explore seamless options like adn to fnp programs, which allow registered nurses to become family nurse practitioners through an accelerated online bridge.

These flexible online pathways help diverse learners begin or advance their medical careers, supporting the healthcare system’s evolving needs.

Best Scientists Citing Quentin M. Anstee

Trending Scientists